Latest Options Exercise News

Buru Energy has secured $5.3 million through a two-tranche placement to fund enhanced development of the Rafael Gas Project, following a significant uplift in project economics from new engineering insights.

High Peak Royalties has secured an upfront A$50,000 option fee from Massive Metals for a 12-month exclusive call option to acquire its Admiral Bay royalty rights, with potential to extend for another year and a total acquisition price of A$2 million.

Antilles Gold has secured $2 million through a share placement to a Chinese investor, strengthening funding for the Nueva Sabana mine construction in Cuba. The capital injection increases the joint venture loan and highlights ongoing financial manoeuvres ahead of mine commissioning.

American Uranium (ASX:AMU) has kicked off a $2.58 million pro rata rights issue at a 3.1% discount to fund expansion drilling and technical studies at its flagship Lo Herma ISR Uranium Project ahead of a Q3 scoping study.

Carbonxt Group has secured $750,000 through convertible notes from major shareholder Phelbe Pty Ltd, targeting expansion of its Minnesota pellet manufacturing and increasing its New Carbon Processing stake to 48.1%.

Solstice Minerals has reported standout Phase 1 drilling at its Nanadie Copper-Gold Project, highlighting wide, high-grade intercepts that surpass current resource grades. Supported by a $32.6 million placement, the company is accelerating Phase 2 drilling to expand this promising WA copper-gold system.

Omnia Metals has made a decisive entry into the US critical minerals market by acquiring the Stibnite Ridge antimony and silver project and staking the Radix rare earth and gallium project in Montana, backed by a $1.5 million capital raise.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Percheron Therapeutics has closed a $2.2 million entitlement offer to advance its HMBD-002 immuno-oncology candidate towards a phase II trial in 2026, backed by strong shareholder and new investor support.

Simble Solutions has finalized its acquisition of Next Nano, issuing 600 million shares to the vendor, while also completing a $2.5 million two-tranche placement with attaching options.